1. Stocks
    2. /
  2. Mesoblast Limited (ASX: MSB)
    3. /

Mesoblast Limited (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Mesoblast Limited (ASX: MSB)
    Latest News

    An old-fashioned panel of judges each holding a card with the number 10
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a happy end to the trading week this Friday.

    Read more »

    Male investor holds a microscope to his eye to represent scrutiny of Wesfarmers share price
    Healthcare Shares

    Mesoblast shares: Bull vs. bear

    | Bronwyn Allen

    Two experts have presented their case for buying and selling the ASX biotech stock.

    Read more »

    A panel of four judges hold up cards all showing the perfect score of ten out of ten
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a happy hump day for the markets.

    Read more »

    Three trophies in declining sizes with a red curtain backdrop
    Share Market News

    Leading analysts name 3 ASX 200 titans to buy today

    | Bernd Struben

    Top analysts forecast strong returns from these three ASX 200 titans. Let’s see why.

    Read more »

    Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
    Healthcare Shares

    Mesoblast shares push higher on strong sales update

    | James Mickleboro

    Sales are growing for this biotech. Let's see what it reported today.

    Read more »

    A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
    Broker Notes

    Should you buy Mesoblast, Paladin Energy, and Xero shares?

    | James Mickleboro

    Analysts have given their verdicts on these shares.

    Read more »

    Turning down AGL shares represented by man placing hands up in front of him and frowning
    Broker Notes

    Brokers say Mesoblast, NAB, and Pilbara Minerals shares are sells

    | James Mickleboro

    These shares have been hit with sell ratings. But why?

    Read more »

    Red sell button on an Apple keyboard.
    Share Market News

    Warning! Analysts name 3 ASX 200 stocks to sell today

    | Bernd Struben

    After a year of outperformance, analysts tip these three ASX 200 stocks as sells. But why?

    Read more »

    Winning woman smiles and holds big cup while losing woman looks unhappy with small cup
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    The ASX surprisingly managed to rise this Monday.

    Read more »

    A woman with a magnifying glass adjusts her glasses as she holds the glass to her computer screen and peers closely at it.
    Opinions

    5 ASX 200 shares I'd buy with $10,000 this week

    | Samantha Menzies

    I have my eye on these stocks this week.

    Read more »

    A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Healthcare Shares

    Mesoblast shares surge 60% in a year. Have investors missed the boat?

    | Samantha Menzies

    Find out if the company is set to experience more growth.

    Read more »

    Three health professionals at a hospital smile for the camera.
    Share Market News

    Mesoblast earnings: surging cell therapy revenues highlight growth

    | Laura Stewart

    Mesoblast shares are in the spotlight after strong revenue growth from Ryoncil® boosted confidence in the company’s outlook.

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Limited

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    Profile

    since

    Note